Volume 2 Supplement 1

International Society on Brain and Behaviour: 1st International Congress on Brain and Behaviour

Open Access

Treatment of psychosis in movement disorders

  • V Kostic1
Annals of General Hospital Psychiatry20032(Suppl 1):S14

https://doi.org/10.1186/1475-2832-2-S1-S14

Received: 1 November 2003

Published: 23 December 2003

Psychotic symptoms, including hallucinations, delusions, delirium, sleep disturbances, are a common problem associated with movement disorders. For instance, psychosis as one of the most disabling levodopa-induced complication occurs in up to 30% of patients with Parkinson's disease (PD). The prevalence of psychotic symptoms in Huntington's disease (HD) ranges from 3.4–30%, while only schizophrenia-like expression was noted in 9% of HD patients. Psychosis can be more disabling than the motor symptoms in patients with movement disorders: it seriously influence the patient's ability to maintain independence and is among the greatest risk factors for nursing home placement. The conventional antipsychotics are poorly tolerated in patients with movement disorders, and in particular in PD patients, since they can induce profound worsening or appearance of parkinsonism and tardive symptoms. The atypical antipsychotic drugs (ie, clozapine, olanzapine, quetiapine, risperidone, etc.) offer improved therapeutic strategy that control psychotic symptoms without compromising motor function

Authors’ Affiliations

(1)
Institute of Neurology in Belgrade

Copyright

© The Author(s) 2003

Advertisement